Tovorafenib: JCA and G-BA benefit assessment compared
The first German benefit assessment after a JCA reveals key differences for tovorafenib in PICO, MAIC, endpoints, data cuts and timing. What this means for the delta dossier.
Insights
EU HTA & AMNOG insights: topics, analysis and guidance for Germany
Choose between current JCA analysis and practical foundations for benefit assessment in Germany.
Choose your perspective
Latest from both topics
JCA Insights
Statutory Health Insurance Contribution Stabilization Act: Implications for AMNOG, Market Access and Dossier Strategy
How manufacturer discounts, price-volume arrangements and rebate contracts affect AMNOG, market access, net revenue and dossier strategy.
AMNOG in Germany
The AMNOG process in Germany
Procedural steps, institutions, timeline and the reimbursement pathway.
AMNOG legislation in Germany
SGB V, AM-NutzenV and the legal framework for benefit assessment and pricing.